Related Experiment Video

Updated: Jul 17, 2025

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.8K

Effects of Moringa Oleifera Leaf Extract Plus Rosiglitazone on Serum Leptin and Glucose and Lipid Metabolism in Type

Can Zhao, Jian-Zhong Zhu, Cui-Rong Song

    Alternative Therapies in Health and Medicine
    |September 7, 2023
    PubMed
    Abstract

    Insights

    Moringa Oleifera Leaf Extract (MOLE) combined with rosiglitazone (RSG) effectively improves glucose and lipid metabolism in type 2 diabetic rats. This combination therapy also enhances the Akt/GSK3β/β-Catenin pathway, offering a promising therapeutic strategy.

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Metabolic Research

    Background:

    • Type 2 diabetes (T2D) is characterized by dysregulated glucose and lipid metabolism.
    • Existing treatments like rosiglitazone (RSG) have limitations.
    • Natural compounds like Moringa Oleifera Leaf Extract (MOLE) show potential in metabolic regulation.

    Purpose of the Study:

    • To evaluate the synergistic effects of MOLE and RSG on metabolic parameters in T2D rats.
    • To investigate the impact on serum leptin and the Akt/GSK3β/β-Catenin signaling pathway.

    Main Methods:

    • Type 2 diabetes was induced in Sprague-Dawley rats using streptozotocin and a high-sugar, high-fat diet.
    • Rats were treated with RSG, varying doses of MOLE, or a combination of MOLE and RSG.
    • Blood glucose, lipid profiles, serum leptin, and key signaling pathway proteins were analyzed.

    Main Results:

    • MOLE and RSG individually improved glucose and lipid metabolism, reduced serum leptin, FFA, and TNF-α compared to the T2D model group.
    • The combination of MOLE and RSG demonstrated superior efficacy over RSG alone in regulating metabolic parameters.
    • The MOLE+RSG group showed enhanced activation of the Akt/GSK3β/β-Catenin pathway.

    Conclusions:

    • Combined MOLE and RSG therapy offers significant benefits for managing hyperglycemia and dyslipidemia in T2D.
    • The synergistic action may involve the modulation of the Akt/GSK3β/β-Catenin signaling pathway.
    • This combination presents a potentially effective therapeutic approach for type 2 diabetes management.

    More Related Videos

    Extraction and Analysis of Taiwanese Green Propolis06:50

    Extraction and Analysis of Taiwanese Green Propolis

    Published on: January 7, 2019

    8.5K
    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

    Published on: November 29, 2024

    654

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    230
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    2.5K
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    357
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    211
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
    183
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    203